[1] Verghese PB, Castellano JM, Holtzman DM. Apolipoprotein E in Alzheimer's disease and other neurological disorders. Lancet Neurol, 2011; 10, 241−52. doi:  10.1016/S1474-4422(10)70325-2
[2] Pericak-Vance MA, St. George-Hyslop PH, Gaskell PC Jr, et al. Linkage analysis in familial Alzheimer disease: description of the Duke and Boston data sets. Genet Epidemiol, 1993; 10, 361−4.
[3] Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science, 1993; 261, 921−3. doi:  10.1126/science.8346443
[4] Li YJ, Hauser MA, Scott WK, et al. Apolipoprotein E controls the risk and age at onset of Parkinson disease. Neurology, 2004; 62, 2005−9. doi:  10.1212/01.WNL.0000128089.53030.AC
[5] Zareparsi S, Kaye J, Camicioli R, et al. Modulation of the age at onset of Parkinson's disease by apolipoprotein E genotypes. Ann Neurol, 1997; 42, 655−8. doi:  10.1002/ana.410420417
[6] Lippa CF, Smith TW, Saunders AM, et al. Apolipoprotein E genotype and Lewy body disease. Neurology, 1995; 45, 97−103. doi:  10.1212/WNL.45.1.97
[7] Kawanishi C, Suzuki K, Odawara T, et al. Neuropathological evaluation and apolipoprotein E gene polymorphism analysis in diffuse Lewy body disease. J Neurol Sci, 1996; 136, 140−2. doi:  10.1016/0022-510X(95)00312-P
[8] Chiò A, Brunetti M, Barberis M, et al. The role of APOE in the occurrence of frontotemporal dementia in amyotrophic lateral sclerosis. JAMA Neurol, 2016; 73, 425−30.
[9] Mahoney-Sanchez L, Belaidi AA, Bush AI, et al. The complex role of Apolipoprotein E in Alzheimer's disease: an overview and update. J Mol Neurosci, 2016; 60, 325−35. doi:  10.1007/s12031-016-0839-z
[10] Govone F, Vacca A, Rubino E, et al. Lack of association between APOE gene polymorphisms and amyotrophic lateral sclerosis: a comprehensive meta-analysis. Amyotroph Lateral Scler Frontotemporal Degener, 2014; 15, 551−6. doi:  10.3109/21678421.2014.918149
[11] Jawaid A, Poon M, Strutt AM, et al. Does apolipoprotein E genotype modify the clinical expression of ALS?. Eur J Neurol, 2011; 18, 618−24. doi:  10.1111/j.1468-1331.2010.03225.x
[12] Siddique T, Pericak-Vance MA, Caliendo J, et al. Lack of association between apolipoprotein E genotype and sporadic amyotrophic lateral sclerosis. Neurogenetics, 1998; 1, 213−6. doi:  10.1007/s100480050031
[13] Mui S, Rebeck GW, McKenna-Yasek D, et al. Apolipoprotein E ϵ4 allele is not associated with earlier age at onset in amyotrophic lateral sclerosis. Ann Neurol, 1995; 38, 460−3. doi:  10.1002/ana.410380318
[14] Zetterberg H, Jacobsson J, Rosengren L, et al. Association of APOE with age at onset of sporadic amyotrophic lateral sclerosis. J Neurol Sci, 2008; 273, 67−9. doi:  10.1016/j.jns.2008.06.025
[15] Moulard B, Sefiani A, Laamri A, et al. Apolipoprotein E genotyping in sporadic amyotrophic lateral sclerosis: evidence for a major influence on the clinical presentation and prognosis. J Neurol Sci, 1996; 139 Suppl, 34-7.
[16] Praline J, Blasco H, Vourc'h P, et al. APOE ε4 allele is associated with an increased risk of bulbar-onset amyotrophic lateral sclerosis in men. Eur J Neurol, 2011; 18, 1046−52. doi:  10.1111/j.1468-1331.2010.03330.x
[17] Drory VE, Birnbaum M, Korczyn AD, et al. Association of APOE ε4 allele with survival in amyotrophic lateral sclerosis. J Neurol Sci, 2001; 190, 17−20. doi:  10.1016/S0022-510X(01)00569-X
[18] Li YJ, Pericak-Vance MA, Haines JL, et al. Apolipoprotein E is associated with age at onset of amyotrophic lateral sclerosis. Neurogenetics, 2004; 5, 209−13. doi:  10.1007/s10048-004-0193-0
[19] Kutakova EV, Zakharova MN, Illarioshkin SN, et al. [The role of apolipoprotein E in patients with amyotrophic lateral sclerosis (a clinical and genetic study)]. Zh Nevrol Psikhiatr Im S S Korsakova, 2009; 109, 51−4.
[20] He D, Shang L, Liu Q, et al. Association of apolipoprotein E ε4 allele and amyotrophic lateral sclerosis in Chinese population. Amyotroph Lateral Scler Frontotemporal Degener, 2022; 23, 399−406. doi:  10.1080/21678421.2021.1953077
[21] Sghaier I, Kacem I, Ratti A, et al. Impact of APOE and MAPT genetic profile on the cognitive functions among Amyotrophic Lateral Sclerosis Tunisian patients. J Neural Transm, 2025; 132, 609−18. doi:  10.1007/s00702-024-02870-3
[22] Maranzano A, Verde F, Dubini A, et al. Association of APOE genotype and cerebrospinal fluid Aβ and tau biomarkers with cognitive and motor phenotype in amyotrophic lateral sclerosis. Eur J Neurol, 2024; 31, e16374. doi:  10.1111/ene.16374
[23] Lacomblez L, Doppler V, Beucler I, et al. APOE: a potential marker of disease progression in ALS. Neurology, 2002; 58, 1112−4. doi:  10.1212/WNL.58.7.1112
[24] Brooks BR, Miller RG, Swash M, et al. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord, 2000; 1, 293−9. doi:  10.1080/146608200300079536
[25] Tortelli R, Copetti M, Panza F, et al. Time to generalisation as a predictor of prognosis in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry, 2016; 87, 678−9. doi:  10.1136/jnnp-2014-308478
[26] Cedarbaum JM, Stambler N, Malta E, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. J Neurol Sci, 1999; 169, 13−21. doi:  10.1016/S0022-510X(99)00210-5
[27] Gordon PH, Cheung YK. Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS. Neurology, 2006; 67, 1314−5. doi:  10.1212/01.wnl.0000243812.25517.87
[28] Ye S, Ji Y, Li CY, et al. The Edinburgh cognitive and behavioural ALS screen in a Chinese amyotrophic lateral sclerosis population. PLoS One, 2016; 11, e0155496. doi:  10.1371/journal.pone.0155496
[29] Chen CL, Hu ZP. ApoE polymorphisms and the risk of different subtypes of stroke in the Chinese population: a comprehensive meta-analysis. Cerebrovasc Dis, 2016; 41, 119−38. doi:  10.1159/000442678
[30] Wang HF, Sun QH, Du RR, et al. Serum Trace Elements and Their Associations with Disease Progression and Survival in Sporadic Amyotrophic Lateral Sclerosis: Insights from a Chinese Cohort. Biomed Environ Sci, 2026; 39, 183−91.
[31] Wang C, Yu JT, Wang HF, et al. Meta-analysis of peripheral blood Apolipoprotein E levels in Alzheimer's disease. PLoS One, 2014; 9, e89041. doi:  10.1371/journal.pone.0089041
[32] Ramassamy C, Averill D, Beffert U, et al. Oxidative insults are associated with Apolipoprotein E genotype in Alzheimer's disease brain. Neurobiol Dis, 2000; 7, 23−37. doi:  10.1006/nbdi.1999.0273
[33] Canosa A, Pagani M, Brunetti M, et al. Correlation between Apolipoprotein E genotype and brain metabolism in amyotrophic lateral sclerosis. Eur J Neurol, 2019; 26, 306−12. doi:  10.1111/ene.13812